ConFlow MedTech Completes $9M Series A Financing to Accelerate Innovation in Cardiovascular Medical Devices

As the old year passes and the new one begins, with the golden tiger ushering in spring, VCBeat (WeChat ID: vcbeat) has learned第一时间 that Shanghai ConFlow MedTech Co., Ltd. has had a series of auspicious events. Recently, Shanghai ConFlow MedTech Co., Ltd. (ConFlow MedTech, hereinafter referred to as "ConFlow MedTech") announced the completion of a nearly 60 million RMB A-round financing. This round of financing was led by Taiyu Yikang Investment, with Tai Kun Fund participating. The funds from this round of financing will be mainly used for pre-clinical and registration clinical trials of ConFlow MedTech's ongoing projects, as well as subsequent independent research and development and transformation of new products. This capital boost will further facilitate the expansion of ConFlow MedTech's innovative product R&D pathway.

ConFlow MedTech has always focused on the R&D, production, and industrial operation of innovative cardiovascular medical devices. By continuously conducting independent research and clinical transformation of cutting-edge high technologies, it is committed to becoming a first-class innovative product manufacturer with international influence. The ConFlow MedTech management team has over a decade of experience in the structural heart disease field, composed of experts in project R&D and production, clinical quality registration, and market sales. The company has applied for more than twenty PCT, invention, and utility model patents. Its headquarters is located in Songjiang Technology City, under the Lingang Group in Shanghai, with a 2,200-square-meter Class 10,000 cleanroom, advanced laboratories, machining platforms, and office spaces. In addition to its shunt device project, which has entered the clinical trial stage, the company’s innovative congenital heart intervention products and valve products have also moved into the animal testing exploration phase, striving to become a differentiated and innovative R&D and production platform for structural heart diseases.

(Shunt Product Image)

ConFlow MedTech's FreeFlow® Percutaneous Atrial Shunt System has successfully conducted multiple clinical trials. Patients experienced significant improvement in heart failure symptoms and cardiac function post-operation, demonstrating remarkable clinical efficacy. This provides heart failure patients with a novel device-based treatment option alongside conventional drug therapy. The FreeFlow® Percutaneous Atrial Shunt System is China's first atrial shunt system featuring rapid endothelialization of the polymer membrane and retrievability for a second time. Its unique elliptical design reduces the implant volume and can be paired with a smaller delivery system. This technology has applied for multiple patents, possesses full independent intellectual property rights, and represents truly indigenous Chinese innovation.

Chen Xiumin, founder of ConFlow MedTech, stated:After a decade of exploration and accumulation, China's innovative cardiovascular medical industry is in a period of accelerated development. The national and local governments have introduced multiple policies to encourage the transformation of medical science and technology and the independent research and development of innovative medical devices. Chinese clinicians, having accumulated rich experience in clinical diagnosis and treatment, have creatively developed various treatment solutions and patented technologies by addressing multiple clinical pain points and incorporating engineering design concepts. Chinese R&D engineers, through practical experience in domestic and international innovative product development, have mastered the entire process of technical development and product R&D. Chinese suppliers, through continuous collaboration with major domestic and international manufacturers, have rapidly improved their technologies and quality in raw materials, processing techniques, and supporting equipment. Driven by the policy of bulk procurement of medical consumables, China’s capital market has further tapped into high-quality projects that are original and innovative. At this moment, as an innovative cardiovascular medical device company based in China with a global perspective, ConFlow MedTech is seizing the opportunity, working pragmatically, and daring to innovate. Relying on its professional R&D team and years of deep involvement in clinical translation, it is bound to secure a place in this wave of technological innovation and achieve more outstanding results in the future.

Dr. Jirong Ji, Founder and General Manager of Taiyu Investment, stated:

Taikun Fund Project Leader Stated:Cardiovascular diseases have always been a key focus in the innovation of medical devices. With the accelerating aging population in China, the number of people suffering from cardiovascular diseases continues to grow, leading to a significant amount of unmet clinical needs. ConFlow MedTech, established by a team of industry veterans, has built a robust R&D pipeline through independent research and scientific transformation since its inception. Its core product, FreeFlow®, has shown remarkable clinical efficacy and is proceeding smoothly. As one of the investors in this round, we will continue to monitor the development and needs of ConFlow MedTech, assist in advancing the R&D of multiple innovative products, and help the company become a leading innovator in cardiovascular medical devices.

Established in 2014, Taiyu Investment is an independent venture capital firm under Tigermed. Focusing on equity investments in early and growth-stage healthcare sectors, the management team of Taiyu Investment possesses profound industry background, extensive industry resources, and rich investment experience. To date, it has completed investments totaling 1.5 billion yuan across nearly a hundred projects, with a portfolio covering medical devices, biopharmaceuticals, CRO, and health foods. By empowering its invested companies, Taiyu Investment creates value for the development of the healthcare industry in China and globally, contributing to public health.

Taikun Fund is a biopharmaceutical industry fund jointly initiated by Tigermed, Hangzhou Capital, and Hangzhou High-Tech Innovation. Relying on Tigermed's industrial layout in clinical CRO and aligning with Hangzhou's pharmaceutical industry development strategy, Taikun Fund operates through market-oriented mechanisms. Focused on the life and health industry, it primarily invests in innovative medical devices, biopharmaceuticals, medical services, medical informatization, digital therapeutics, intelligent manufacturing, and nutrition and health enterprises.